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Abstract
Crohn’s disease (CD) activity assessments are dominated by inflammatory changes without discrete measurement of the
coexisting fibrotic contribution to total bowel damage. Intestinal fibrosis impacts the development of severe structural
complications and the overall natural history of CD. Measuring intestinal fibrosis is challenging and existing methods of
disease assessment are unable to reliably distinguish fibrosis from inflammation. Both the immediate clinical need to
measure fibrosis for therapeutic decision-making and the near-future need for tools to assess pipeline anti-fibrotic medi-
cations highlight the demand for biomarkers of fibrosis in CD. Developing non-invasive technologies exploit changes in
intestinal perfusion, mechanical properties, and macromolecular content to provide quantitative markers of fibrosis. In this
review of existing and experimental technologies for imaging intestinal fibrosis, we discuss the expanding capabilities of
quantitative MR and ultrasound imaging, encouraging developments in non-invasive elastography, and emerging novel
methods including photoacoustic imaging.
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Introduction
Crohn’s disease (CD) is classically considered an idio-
pathic illness of intermittent segmental intestinal
inflammation. Transmural bowel wall injury is also
impacted by wound healing mechanisms which result
in the development of cumulative and irreversible intes-
tinal fibrosis. Over time, inflammation and fibrosis
together cause progressive bowel wall thickening, stric-
ture development, and obstructing and penetrating
complications.1 An argument could be made that intes-
tinal fibrosis is most responsible for a complicated and
disabling CD course, considering that despite the
introduction of anti-tumor necrosis factor alpha
(TNF) therapies to control inflammation, surgical
rates have not changed in nearly 20 years in the
USA.2 The complexity of CD management decisions
are often related to our inability to determine the rela-
tive contribution of inflammation and fibrosis in a
damaged bowel segment. The degree of intestinal fibro-
sis present underlies common clinical questions for
individual patients: What is the appropriate therapeutic
intensity at diagnosis? Is the current therapeutic
regimen sufficient to prevent future structural compli-
cations? Will increasing therapeutic intensity in the set-
ting of existing stricturing disease be sufficient to
prevent surgery? This review will discuss existing, emer-
ging, and experimental imaging methods to detect and
measure intestinal fibrosis in CD.
The challenges of assessing intestinal fibrosis
Because of the inability of ileocolonoscopy with biopsy
to interrogate transmural injury, cross-sectional ima-
ging methods, including ultrasound (US), computed
tomography enterography (CTE), and magnetic reson-
ance enterography (MRE), have become essential com-
panions to endoscopy.3,4 Excellent image-based disease
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activity assessments, including the magnetic resonance
index of activity (MaRIA), are strongly correlated
with endoscopic activity, but principally score inflam-
matory factors.5 Yet, the concept that a high or low
degree of bowel wall contrast enhancement is charac-
teristic of predominantly inflammatory or fibrotic
intestinal disease has been questioned. Adler and col-
leagues, along with other groups, have showed that
that the radiologist global impression of whether a
stricture was ‘‘active’’ or ‘‘inactive’’ was not associated
with the presence or degree of fibrosis.6,7 The Lémann
index represents an international effort to more com-
prehensively describe total bowel damage accounting
for stricturing and penetrating disease using imaging.8
However, obvious strictures represent late stage
macroscopic events, when the window for medical
intervention is nearing closure. Further, claims that
bowel dilation is associated with the degree of intes-
tinal fibrosis remain controversial.9 One could make a
pragmatic argument that treating to an endpoint of
objective resolution of inflammation to halt the pro-
gression of fibrosis is sufficient. However, emerging
data raises the possibility that while inflammation
may initiate fibrogenesis, for poorly understood rea-
sons, fibrosis could auto-propagate even after inflam-
mation is extinguished.10 Taken together, these points
capture the need to objectively measure intestinal
fibrosis. Given our inability to safely and routinely
obtain full thickness intestinal samples, several meth-
ods are being explored to provide a ‘‘virtual biopsy,’’
relying on changes in tissue perfusion, mechanics, and
macromolecular composition as surrogate biomarkers
of fibrosis.
Perfusion as a surrogate for intestinal fibrosis
The neovascularization and changes in vascular auto-
regulation observed in intestine affected by CD have
been studied as methods to grade histologic inflamma-
tion.11 Fibrotic histologic changes are hypothesized to
retard blood flow. Careful quantitation of perfusion
dynamics using traditional MRE methods has yielded
encouraging data supporting its use as a marker of
fibrosis. Comparing MRE to graded histology in 41
resected specimens, Rimola and colleagues found that
imaging findings of inflammation, including high T2
signal, mucosal hyper-enhancement, and the presence
of ulcerations, were associated with the histologic
grade of inflammation (p¼ 0.02, 0.03, <0.01, respect-
ively) but not the grade of fibrosis (p¼ 0.57, 0.60, 0.85,
respectively).12,13 Alternatively, delayed progressive
enhancement over a 7-minute observation period sepa-
rated low- and high-grade fibrosis (14% vs. 35%
enhancement gain, p< 0.01) but not inflammation.
The authors also show that using high T2 signal
intensity to grade inflammation and delayed pro-
gressive enhancement to grade fibrosis can together
coarsely classify intestine histology, moderately
agreeing with paired tissue sample analysis (k¼ 0.59,
95% CI 0.40–0.77).
An alternative method of assessing tissue inflamma-
tion, diffusion weighted imaging (DWI), has also been
studied as a quantitative method of assessing inflamma-
tion and may provide a method to distinguish inflam-
mation from fibrosis.14 In a small study of 28 CD
patients undergoing elective surgical resection, the
mean apparent diffusion coefficient (ADC) of fibrotic
vs. non-fibrotic tissue was 2282 (1998–2772) and 1714
(1433–2311), respectively, p¼ 0.023.15 The linear correl-
ation between ADC and the degree of inflammation by
histology was not statistically significant (p¼ 0.090),
though a trend of decreasing ADC with increasing
inflammation score was observed. At this juncture it
is unclear whether DWI can discriminate intestinal
fibrosis from inflammation sufficiently enough to be
clinically meaningful. The most notable limitation of
the these and other studies investigating fibrosis bio-
markers is that the requirement for full thickness hist-
ology limits subjects to those undergoing surgery for
intractable disease. Study samples are therefore biased
towards moderate to severe fibrosis and few specimens
contain intestinal damage dominated by inflammation;
only 3/41 subjects had grade 1 fibrosis in the Rimola
et al. study. The lack of access to full thickness hist-
ology, over a spectrum of disease durations and seve-
rities, remains a key hurdle in intestinal fibrosis
research.
Tissue perfusion characteristics can also be assessed
by ultrasound. Contrast-enhanced ultrasound (CE-US)
uses intravenously administered microbubbles which
can be quantified and standardized using image ana-
lysis platforms (Figure 1).16 Readouts can provide not
only peak contrast values, but also tissue perfusion kin-
etics; this is a more objective and quantitative method
than traditional Doppler US (Figure 1). A 14 patient
study of CE-US showed that delayed contrast wash-in
(p¼ 0.02) and wash-out (p¼ 0.008) were associated
with therapeutic non-response, though no full thickness
histology was available.17 A 39 subject study where
patients were dichotomized as being predominantly
fibrotic (requiring elective surgery for refractory stric-
turing disease), or inflammatory (no strictures, but
required steroid or anti-TNF), found those judged to
be fibrotic had a slower rate of perfusion compared to
the inflammatory group (22.6 vs. 45.3mL/min per
100mL, p¼ 0.003).18 The same group found that the
ratio of intestinal tissue perfusion to bowel wall thick-
ness (cutoff of 0.56mL/min/mm) predicted surgical vs.
medically managed disease with an AUROC of 0.92
and sensitivity and specificity 82% and 94%, respectively.
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These CE-US studies presented are subject to error
stemming from using clinical decisions, outcomes,
and unverified gold standards as surrogates of fibrosis.
It is also possible that the imaging findings influenced
clinical decision making, biasing the results toward
reporting an inflated accuracy. Though longitudinal
studies and more histopathology correlates are
needed, tissue perfusion characteristics quantified by
MRE and CE-US appear correlated with intestinal
fibrosis.
Tissue elasticity as a surrogate for
intestinal fibrosis
The excess deposition of extracellular matrix along
with disorganized smooth muscle proliferation
together contribute to changes in the mechanical prop-
erties of fibrostenotic intestinal damage. Direct meas-
urement of intestine elasticity in animal models and
ex-vivo human CD intestinal specimens have shown
the degree of fibrosis is associated the degree of
tissue stiffness.19 This correlation has drawn attention
to the use of non-invasive stiffness measurement as a
surrogate marker of fibrosis. Ultrasound strain ima-
ging quantifies the ‘hardness’ or ‘softness’ of a tissue
as a function of tissue compressibility. Using a two-
dimensional speckle tracking technique for quantita-
tion of tissue distensibility, non-invasive strain assess-
ment strongly correlated with direct stiffness
measurements of intestine.20 Using the TNBS rat
model of intestinal injury, ultrasound strain imaging
was able to distinguish inflamed from fibrotic-
inflammatory tissue (2.07 vs. 1.10, p¼ 0.037) and
also correlated with the presence of fibrosis in a
small human pilot (¼ 0.81, p¼ 0.008). An important
limitation of this bowel elastography technique was
that it does not produce real time results, requiring
extensive post-study image processing.
New approaches to elastography are being investi-
gated to determine their ability to measure intestinal
fibrosis and predict therapeutic responsiveness in CD.
In a small study of 10 CD patients undergoing intes-
tinal resection, real-time ultrasound elastography
(US-RTE) was shown to be associated with the
degree of muscularis thickness (p¼ 0.006), Masson’s

















Figure 1. Contrast enhanced ultrasound (CE-US) has demonstrated some promise in providing better measurement of intestinal
inflammation based on quantitation of perfusion characteristics. Perfusion kinetics, including inflow, outflow, and flow rate, can all be
assessed within an area of interest. CE-US is being explored as a means to separate inflammation from fibrosis in Crohn’s disease.
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quantitation of high vs. low collagen content by west-
ern blot (2.01 vs. 0.87, p¼ 0.009).21 US-RTE offers
advantages of immediate bedside results and stand-
ardization of applied freehand force by using a pres-
sure-sensitive transducer. Shear wave elastography
(SWE) is an alternative technique that generates an
ultrasonic pressure wave (using acoustic radiation
force impulse) which can be focused on a specific
region of bowel wall. The resulting orthogonal shear
wave speed through the tissue can be measured;
increasing speed is correlated with increasing tissue
density and stiffness (Figure 2). SWE has also demon-
strated an ability to distinguish fibrotic and inflamma-
tory intestinal damage in animal models with an
AUROC of 0.971, exhibiting a PPV and NPV of
95.0% and 92.9%.22 In addition, shear wave speed
has been shown to modestly correlate with the histo-
logic grade of fibrosis (¼ 0.60, p¼ 0.01), but not
inflammation (¼ 0.24, p¼ 0.36) in ex-vivo human
intestinal specimens.23 A recent study of 23 patients
undergoing surgical resection found elastography able
to distinguish severe fibrosis from inflammation,
though it was unable to separate mild-moderate histo-
logic fibrosis from predominantly inflammatory dis-
ease.24 Much more study is needed prior to
incorporating elastography into routine clinical care,
including establishing reproducibility, dynamic range,
the ability to quantify intermediate gradations of
fibrosis, and ultimately predict natural history and
clinical outcomes in CD.
PET and metabolic imaging for
intestinal fibrosis
Positron emission tomography (PET), commonplace
in oncologic follow-up, has been investigated as a
method to differentiate predominantly inflammatory
from fibrostenotic bowel damage. Fluorodeoxyglucose
(FDG)-PET, combined with CT or MR for anatomic
localization, has been explored under the hypothesis
that inflammatory tissue will have increased metabolic
activity compared to fibrotic bowel. Small pilot studies
to date have demonstrated mixed, generally
discouraging, results for PET-imaging to distinguish
inflammation from fibrosis. A recent study showed
that PET-MR in 19 patients undergoing elective
bowel resection was able to predict the histology of
resected segments (fibrosis alone vs. a mixed fibro-
inflammatory disease), albeit with underwhelming
diagnostic accuracy (sensitivity 0.67, specificity
0.73).25 Lenze and colleagues prospectively evaluated
PET-CT, MR-enteroclysis, and B-mode ultrasound
for characterizing stricturing disease and predicting
therapeutic outcomes. While non-significant trends in
their data suggested some ability of all modalities to
predicting medical response vs. surgical management
within 6 months, no single technique was superior.26
Considering the cost, radiation exposure, and marginal
performance, traditional metabolic imaging by FDG-
PET has not demonstrated the potential for fibrosis
detection relative to other modalities.
Figure 2. Ultrasound stiffness imaging using shear wave speed measurement. In shear wave imaging, an ultrasonic pulse is directed
at a region of interest, generating a shear wave within the tissue that can be measured by the transducer. A ileal stricture is shown
by traditional B-mode scan (left) with real-time quantitation of shear wave speed within the scan field (right). Shear wave speed is
correlated to tissue stiffness, which itself is associated with the degree of fibrosis.
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Experimental techniques: direct
macromolecule detection
Methods discussed thus far have explored surrogates
of fibrosis which remain susceptible to variations in
coexistent inflammation. Exciting new directions in
macromolecule detection, specifically collagen, offer a
more direct measurement of fibrosis. Magnetization
transfer MR imaging (MT-MRI) is an alternative con-
trast technique that detects the exchange of protons
(magnetization) between fixed macromolecules and
surrounding free water within a tissue.27 In this way,
MT-MRI can detect collagen and other large macro-
molecules. Adler and colleagues showed that MT-MRI
was able to quantify fibrosis and distinguish fibrosis
from inflammation in an animal model of intestinal
injury, with a PPV and NPV of 92% and 83%.28
MT-MRI correlated well with both histologic scoring
(¼ 0.74) and collagen quantitation (¼ 0.72).
Subsequent studies improved the histologic discrimin-
ation of MT-MRI by adding a marker of inflamma-
tion, T2 weighted signal intensity, with a resulting
AUROC of 0.98 for detecting bowel wall fibrosis in
the TNBS rat model of intestinal damage (Figure
3).29 Pilot studies have demonstrated the feasibility
of MT-MRI in humans for separation of predomin-
ately inflammatory and fibrotic intestinal damage.30
In line with the limitations of fibrosis research dis-
cussed, these human pilots use surrogate endpoints
themselves (radiologist definition of fibrotic vs. inflam-
matory). Within these limitations, MT-MRI, a tech-
nique available with existing hardware that incurs no
additional cost, provides a novel method for fibrosis
measurement in CD.
Another experimental method gaining attention for
molecular quantitation is photoacoustic imaging (PAI).
PAI uses pulsed laser light to penetrate tissues at vari-
able depths. The resulting molecular vibrations pro-
duced in the megahertz range can be detected by
ultrasound for macromolecular signatures and two- or
three-dimensional image production.31 Exploiting the
threefold difference in the optical absorption of hemo-
globin (a molecular proxy for blood flow and inflam-
mation) and collagen (a molecular proxy for fibrosis) at
532 nm and 1370 nm, PAI may provide a means to con-
trast hemoglobin and collagen from surrounding
macromolecules and thus quantify fibrosis. Using the
TNBS-rat model of intestinal injury, PAI at 1370 nm
exhibited a 2.9-fold increase in average pixel intensity
within mixed fibro-inflammatory intestinal segments
compared to pure inflammatory injury, p< 0.0001
(Figure 4).32 Several technical challenges remain,
including adjusting for the optical absorption of water
(near 1300 nm), and a more efficient means of laser light
delivery with tandem ultrasound. Human studies of
PAI in CD are planned, using endoscopically delivered
laser light combined with transabdominal and endo-
scopic ultrasound.
Endomicroscopy with molecular tagging is an excit-
ing imaging method on the horizon with potential
applications in CD. Atreya and colleagues recently
showed the ability to perform in vivo membrane-
bound TNF measurement using florescent antibodies


























Figure 3. Magnetization transfer (MT) MRI for quantifying fibrosis. MT-MRI detects heavy macromolecules within a tissue, including
collagen. In the TNBS-rat model of intestinal inflammation and fibrosis, a parametric map of calculated MT-ratios shows the bowel
(arrows) having less MT effect than surrounding muscle, but more than fat and fluid in the bladder (B). The relationship between
T2-weighted signal intensity and MT-ratio (left) provides good discrimination between inflammatory and mixed fibro-inflammatory
disease of the bowel wall in this animal model.29
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In 25 subjects, anti-TNF responders had a mean of 30
TNFþ cells per field compared to 11 TNFþ cells in
non-responders (p¼ 0.0004). While molecular tagging
and real-time confocal histology is presently restricted
to the mucosa and submucosa, molecular tagging
within the bowel has been accomplished in IBD.
Apoptosis was assessed in animal models and 14
humans using IV administration of technetium-99m-
annexin V followed by CT-scintigraphy prior to anti-
TNF treatment.34 Subjects with anti-TNF response
exhibited 98.7% bowel uptake of 99mTc-annexin V in
affected segments compared to 15.2% in non-respon-
ders. Radiolabeling techniques could conceivably be
applied to constituents of fibrosis. Finally, emerging
nanotechnology is providing additional tools for intes-
tinal assessment. Nanoparticles can be engineered for
high-affinity tissue or molecular binding, can be
detected by multiple non-ionizing methods, and are
stable enough for both intravenous and oral adminis-
tration.35 Orally administered nanoparticles have been
used as a photoacoustic contrast agent to improve
bowel motility assessments, with the potential for add-
itional sophisticated intestinal imaging applications.36
Concepts of CD activity are evolving from isolated
objective measures of inflammation to current efforts to
objectively measure cumulative total bowel damage.
Accurate and sufficiently dynamic measures of intestinal
fibrosis will have an immediate impact in our under-
standing of the natural history of CD and an individual’s
prognosis. Objective fibrosis measures will help guide
decisions regarding both medical vs. surgical treatment,
as well as the intensity of therapy needed to avoid disease
complications. Finally, we are on the cusp of anti-fibro-
tic therapies. Pirfenidone and nintedanib, small mol-
ecules that inhibit or downregulate key mechanisms of
fibrosis, are now approved by the EMAandFDA for the
treatment of idiopathic pulmonary fibrosis. The bowel
imaging techniques presented will needed to evaluate the
efficacy of candidate anti-fibrotic therapies in CD.
Independentmeasurements of inflammation and fibrosis
will together provide a more comprehensive description
of intestinal damage for increasingly precise and indivi-
dualized treatment of CD.
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